Unraveling the Therapeutic Prospects of Solid Lipid Nanoparticles for the Treatment of Parasitic Diseases

Abstract

Parasites induce a spectrum of illnesses, ranging from mild to severe, often causing significant global outbreaks. Existing antiparasitic drugs exhibit toxicity and notable side effects. Nanocarriers offer a promising solution by mitigating these issues through reduced side effects, enhanced target delivery, and additionally regulated prolonged active ingredient release. Solid lipid nanoparticles (SLNs), a subset of lipid nanoparticles (LNPs), have gained prominence for their favorable attributes. SLNs present themselves as a feasible option among colloidal carriers, offering an optimal release rate, stability, and precise target delivery. Their potential to deliver natural antiparasitic products is particularly noteworthy. Recent advancements in utilizing nanoparticles to enhance SLN stability and loading capacity are also explored in this review. The narrative encompasses SLN development, preparation methods, characterization, and the incorporation of drugs for combating parasitic diseases, offering insights into the evolving landscape of antiprotozoal SLN-saturated medications